Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Evotec AG

Apr 2010
Evotec AG of Hamburg, Germany, has announced that it is collaborating with Active Biotech AB to identify small-molecule modulators of a priority biological target involved in immune disorders and cancer. The former, a drug discovery company, will use its technologies in assay development and high-throughput and surface plasmon resonance screening to identify and validate novel hits. It will screen its Lead Discovery Library, a small-molecule collection, to maximize the probability of finding medicinal chemistry starting points. Active Biotech of Lund, Sweden, develops pharmaceuticals for diseases of the immune system.

See acousto-optic modulator; electro-optic modulator.
Active BiotechBasic SciencebiologicalBiophotonicsBusinesscancercollaborationdiseasedrug discoveryEuropeEvotec AGGermanyimmune disorderimmune systemLead Discovery LibrarymodulatorpharmaceuticalsRapidScanscreeningsmall-molecule modulatorssurface plasmon resonance screeningSweden

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.